In preparation
INtrODUCtION
Several studies have shown a correlation between the efficacy and safety of voriconazole and voriconazole trough concentrations (1-8). Based on these studies a voriconazole trough concentration above 1.5 mg/L is recommended, as this is associated with a favorable response (4). Voriconazole trough concentrations above 5.0 mg/L should be avoided as these are associated with an increased incidence of adverse events, such as visual disturbances and hallucinations (1).
Therapeutic drug monitoring may be helpful to optimize treatment because of the large inter-and intra-individual variability in voriconazole concentrations (9, 10) and the relation between voriconazole trough concentrations and efficacy and safety. Therefore, the Infectious Diseases Society of America guidelines recommend determination of voriconazole concentrations, in conjunction with clinical assessments to evaluate potential toxicity or to document adequate voriconazole exposure (11) . A recent randomized controlled study showed that routine therapeutic drug monitoring of voriconazole may reduce drug discontinuation due to adverse events and improve the treatment response in invasive fungal infections (5).
Routine therapeutic drug monitoring of voriconazole could therefore be advocated, especially in critically ill patients since several of the elucidated mechanisms for the pharmacokinetic variability are frequently present in these patients, as impaired liver function (12), drug-drug interactions (13) and inflammation (14) . We speculate that voriconazole therapeutic drug monitoring in routine intensive care unit (ICU) practice can be improved.
The aim of this retrospective study was to investigate the routine practice of voriconazole therapeutic drug monitoring on the ICU and derive possible recommendations for improvement.
PatIeNtS aND MethODS
A retrospective chart review was performed for all patients aged ≥ 18 years that For each eligible patient, data were collected from the medical chart, including demographic data, medical history and voriconazole trough concentrations.
Voriconazole serum concentrations were measured using a validated liquid chromatography tandem-mass spectrometry method (15) . Data that were collected from the medical chart were underlying disease, indication for treatment, The timing of the measured voriconazole concentrations is illustrated in figure 1 .
Remarkably, 66% of the first samples were taken before day 4, at which steady-state was expected in patients receiving a loading dose.(19) Almost half (48%) of the subsequent voriconazole trough concentrations were measured prematurely. stewardship is urgently needed after they observed that the selection and duration of antifungal therapy was substandard (23). We expect that voriconazole therapeutic drug monitoring could as well benefit from antifungal stewardship.
The retrospective nature and its consequent incompleteness of data may be considered as limitations. However, the aim of our study was to investigate the clinical application of therapeutic drug monitoring as several studies already showed the relation between treatment outcome and voriconazole concentrations (1-4, [6] [7] [8] and also the effect of therapeutic drug monitoring on treatment outcome (5).
In conclusion, the performance of voriconazole therapeutic drug monitoring can still be improved although voriconazole concentrations were monitored in most patients. A multidisciplinary approach -for instance by means of antifungal stewardship will probably be able to overcome encountered problems like timing of sampling, incompleteness of data on clinical context and lack of implementation of recommendations. 
